Case report of fatal myocarditis with toripalimab and axitinib combination therapy
Open Access
- 26 December 2025
- journal article
- case report
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (52) , e46439
Abstract
Rationale: Cardiac immune-related adverse events (irAEs) are rare but potentially life-threatening complications of immune checkpoint inhibitor (ICI) therapy, with myocarditis associated with particularly high mortality even under aggressive treatment. Patient concerns: A 65-year-old male with advanced clear cell renal cell carcinoma and liver metastasis presented with progressive wheezing and fatigue following 4 cycles of combination therapy with toripalimab and axitinib, symptoms that failed to respond to conventional supportive measures. Diagnoses: Grade 4 ICI-associated myocarditis was confirmed through a combination of clinical manifestations, characteristic echocardiographic abnormalities, elevated cardiac biomarkers, and the exclusion of infectious causes via comprehensive serological evaluation. Interventions: The patient received multimodal immunosuppressive and supportive therapy, including high-dose methylprednisolone, intravenous immunoglobulin (IVIG), venoarterial extracorporeal membrane oxygenation (VA-ECMO), and therapeutic plasma exchange. Concurrently, broad-spectrum antibiotics were administered based on continuous microbial surveillance. Outcomes: Although transient hemodynamic stabilization was achieved, the patient subsequently developed severe nosocomial infections and progressive multiorgan failure, leading to death on day 24 of hospitalization. Lessons: This case underscores the necessity for early recognition and intensive monitoring in managing high-grade ICI-associated myocarditis. It further highlights the critical role of infection prevention strategies, particularly the implementation of microbial surveillance-guided antibiotic prophylaxis, in patients undergoing combination immunotherapy regimens. Plain Language Summary: We report a 65-year-old male with advanced renal cell carcinoma who developed ICI-associated myocarditis following 4 cycles of combination immunotherapy. The patient presented with progressive dyspnea and fatigue, necessitating hospitalization. Comprehensive diagnostic evaluation confirmed grade 4 myocarditis based on clinical features, elevated cardiac biomarkers, echocardiographic abnormalities, and exclusion of infectious causes. Treatment consisted of multimodal immunosuppressive and life-support therapies, including high-dose methylprednisolone, intravenous IVIG, therapeutic plasma exchange, VA-ECMO, and empiric broad-spectrum antibiotics guided by microbial surveillance. Despite transient hemodynamic stabilization, the patient ultimately progressed to multiorgan failure and died on day 24 of hospitalization. This case underscores the life-threatening nature of ICI-associated myocarditis and highlights the critical need for early recognition, aggressive supportive management, and proactive anti-infective prophylaxis in patients receiving combination immunotherapy.Keywords
This publication has 17 references indexed in Scilit:
- Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-AnalysisFrontiers in Immunology, 2022
- Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of ToripalimabFrontiers in Immunology, 2022
- Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature ReviewFrontiers in Oncology, 2022
- Case Report: A Case Report and Literature Review on Severe Bullous Skin Reaction Induced by anti-PD-1 Immunotherapy in a Cervical Cancer PatientFrontiers in Pharmacology, 2021
- Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab TreatmentFrontiers in Cardiovascular Medicine, 2021
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020Journal of the National Comprehensive Cancer Network, 2020
- Toripalimab: First Global ApprovalDrugs, 2019
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- Immune Checkpoint Inhibitor-Associated MyocarditisThe Oncologist, 2018
- Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesEuropean Heart Journal, 2013